PT - JOURNAL ARTICLE AU - Olbrich, Laura AU - Castelletti, Noemi AU - Schälte, Yannik AU - Garí, Mercè AU - Pütz, Peter AU - Bakuli, Abhishek AU - Pritsch, Michael AU - Kroidl, Inge AU - Saathoff, Elmar AU - Noller, Jessica Michelle Guggenbuehl AU - Fingerle, Volker AU - Le Gleut, Ronan AU - Gilberg, Leonard AU - Brand, Isabel AU - Falk, Philine AU - Markgraf, Alisa AU - Deák, Flora AU - Riess, Friedrich AU - Diefenbach, Max AU - Eser, Tabea AU - Weinauer, Franz AU - Martin, Silke AU - Quenzel, Ernst-Markus AU - Becker, Marc AU - Durner, Jürgen AU - Girl, Philipp AU - Müller, Katharina AU - Radon, Katja AU - Fuchs, Christiane AU - Wölfel, Roman AU - Hasenauer, Jan AU - Hoelscher, Michael AU - Wieser, Andreas AU - On behalf of the KoCo19-Study Team TI - A Serology Strategy for Epidemiological Studies Based on the Comparison of the Performance of Seven Different Test Systems - The Representative COVID-19 Cohort Munich AID - 10.1101/2021.01.13.21249735 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.13.21249735 4099 - http://medrxiv.org/content/early/2021/01/16/2021.01.13.21249735.short 4100 - http://medrxiv.org/content/early/2021/01/16/2021.01.13.21249735.full AB - Background Serosurveys are essential to understand SARS-CoV-2 exposure and enable population-level surveillance, but currently available tests need further in-depth evaluation. We aimed to identify testing-strategies by comparing seven seroassays in a population-based cohort.Methods We analysed 6,658 samples consisting of true-positives (n=193), true-negatives (n=1,091), and specimens of unknown status (n=5,374). For primary testing, we used Euroimmun-Anti-SARS-CoV-2-ELISA-IgA/IgG and Roche-Elecsys-Anti-SARS-CoV-2; and virus-neutralisation, GeneScript®cPass™, VIRAMED-SARS-CoV-2-ViraChip®, and Mikrogen-recomLine-SARS-CoV-2-IgG, including common-cold CoVs, for confirmatory testing. Statistical modelling generated optimised assay cut-off-thresholds.Findings Sensitivity of Euroimmun-anti-S1-IgA was 64.8%, specificity 93.3%; for Euroimmun-anti-S1-IgG, sensitivity was 77.2/79.8% (manufacturer’s/optimised cut-offs), specificity 98.0/97.8%; Roche-anti-N sensitivity was 85.5/88.6%, specificity 99.8/99.7%. In true-positives, mean and median titres remained stable for at least 90-120 days after RT-PCR-positivity. Of true-positives with positive RT-PCR (<30 days), 6.7% did not mount detectable seroresponses. Virus-neutralisation was 73.8% sensitive, 100.0% specific (1:10 dilution). Neutralisation surrogate tests (GeneScript®cPass™, Mikrogen-recomLine-RBD) were >94.9% sensitive, >98.1% specific. Seasonality had limited effects; cross-reactivity with common-cold CoVs 229E and NL63 in SARS-CoV-2 true-positives was significant.Conclusion Optimised cut-offs improved test performances of several tests. Non-reactive serology in true-positives was uncommon. For epidemiological purposes, confirmatory testing with virus-neutralisation may be replaced with GeneScript®cPass™ or recomLine-RBD. Head-to-head comparisons given here aim to contribute to the refinement of testing-strategies for individual and public health use.Competing Interest StatementAW and MH report personal fees and non-financial support from Roche Diagnostics, LO reports non-financial support from Roche Diagnostics. AW, MH and LO report non-financial support from Euroimmun, non-financial support from Viramed, non-financial support from Mikrogen. AW, MH, LO report grants, non-financial support and other from German Center for Infection Research DZIF, grants and non-financial support from Government of Bavaria, non-financial support from BMW, non-financial support from Munich Police, non-financial support and other from Accenture. JH reports grants from German Federal Ministry of Education and Research, during the conduct of the study. MH and AW report personal fees and non-financial support from Dr.Box-Betrobox, non-financial support from Dr. Becker MVZ during the conduct of the study. In addition, MH, AW, MB have a patent on a sample system for sputum diagnostics of SARS-CoV-2 pending. AW is involved in other different patents and companies not in relation with the serology of SARS-CoV-2. AW reports personal fees and other from Haeraeus Sensors, non-financial support from Bruker Daltonics, all of which are outside the submitted work, and non-related to SARS-CoV-2. MB is an authorized representative partner of Dr. Becker MVZ.Clinical TrialDRKS00021698Clinical Protocols https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-020-09164-9 Funding StatementBavarian State Ministry of Science and the Arts, University Hospital, LMU Munich, Helmholtz Centre Munich, University of Bonn, University of Bielefeld, German Ministry for Education and Research (proj. nr.: 01KI20271). Euroimmun, Roche, Mikrogen, Viramed provided kits and machines for analyses at discounted rates.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Commission of the Faculty of Medicine at LMU Munich, Germany (20-275-V).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are accessible subject to data protection regulations upon reasonable request to the corresponding author. To facilitate reproducibility and reuse, the code used to perform the analyses and generate the figures was made available on GitHub (https://github.com/koco19/lab_epi) and has been uploaded to ZENODO (http://doi.org/10.5281/zenodo.4300922, DOI 10.5281/zenodo.4300922) for long-term storage. https://github.com/koco19/lab_epi